Viseven announced a new AI agent for its content creation platform eWizard. The new agent, called eVa, is able to communicate ...

RESVIA is now authorized for use in adults aged 18–59 years with an increased risk of respiratory syncytial virus-related ...

Keytruda marks the first perioperative anti-PD-1 treatment option for adults with PD-L1–positive resectable locally advanced ...

Approval of Zusduri was based on data from the Phase III ENVISION trial, which showed a 78% complete response at three months ...

The company focuses on specialty drugs and uses a combination of AI and human expertise to automate the process.

Under terms of the deal, Bharat Biotech will lead late-stage development and scale-up of the altSonflex1-2-3 Shigella vaccine ...

Mavyret marks the first and only direct-acting antiviral approved to treat both acute and chronic hepatitis C virus ...

Approval was based on results from the Phase II TRUST-I and TRUST-II trials, which demonstrated confirmed overall response ...

In that light, the GLP-1 rebound effect is not an obstacle but an opportunity to chart a new, holistic course in obesity care ...

Marvel Comics announced a new comic book starring a superhero that lives with type 1 diabetes. The project is being developed ...

Delivered as a once-daily 30 mg/mL IV bolus injection over 15 seconds, Xifyrm can be used alone or alongside non-NSAID ...

Regulatory action was based on data from the Phase III IMforte trial, which showed that Zepzelca plus Tecentriq significantly ...